With this background in mind, it would seem that VEGF pathway targeting drugs have anti-tumor activity, albeit limited, against breast cancer in many circumstances, and as such, provides a rationale for devising strategies to improve their impact. This evidence concerns the gene VEGFA and breast carcinoma.